GHRP-6

Description

CAS Number: 87616-84-0
Molecular Formula: C46H56N12O6
Molecular Weight: 873.01 g/mol
Form: Lyophilized Powder
Quantity: 10mg
Purity: ≥ 98 percent (HPLC Verified)

Product Overview

GHRP-6, also known as Growth Hormone Releasing Peptide-6, is a synthetic hexapeptide that binds to the ghrelin receptor GHS-R1a and stimulates growth hormone release from the pituitary. It is widely studied for its strong influence on appetite signaling in addition to its effects on GH and IGF-1 pathways. Research often compares GHRP-6 to GHRP-2, with GHRP-6 showing higher activity in hunger modulation while still supporting pulsatile GH secretion.

Applications in Research

Growth hormone release and secretion pattern models Appetite signaling and metabolic adaptation studies Muscle recovery and tissue repair investigations Synergistic models using GHRH analogs such as CJC-1295

Storage and Handling

Store the lyophilized material at minus 20°C in a dry and dark location. Reconstitute with sterile bacteriostatic water. After reconstitution, keep refrigerated and use within recommended laboratory timelines. Avoid repeated freeze and thaw cycles.

Research Use Only – Legal Disclaimer

All Eagle Peptides products labeled as Research Use Only (RUO) are intended strictly for laboratory, investigational, and scientific research purposes. These materials are not approved by the FDA and are not intended for human or veterinary use, clinical applications, diagnostic procedures, or therapeutic treatment of any kind. By purchasing or using RUO materials, you acknowledge that they will be handled only within an appropriate research environment by qualified personnel who understand the risks, limitations, and regulatory requirements associated with experimental compounds. Products must not be administered to humans or animals, offered as therapeutic agents, or represented as safe or effective for any medical purpose. Use of these materials is entirely at your own risk. Eagle Peptides assumes no liability for misuse, unsafe handling, improper application, or any regulatory or compliance issues arising from their use.